Dustin Hammers


Associate Professor, Department of Neurology, Indiana University School of Medicine

Dustin B. Hammers is a board-certified clinical neuropsychologist and Associate Professor in the Department of Neurology at Indiana University (IU). Joining the department in 2021, he was previously faculty at the University of Utah starting in 2011. Dr. Hammers is the primary neuropsychologist involved in the NIA-funded Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS), and he is currently the Principal Investigator on the NIA- and Alzheimer’s Association–funded study Lifestyle Interventions for the Treatment of Early-Onset AD Study (LITES). His research has emphasized the evaluation of diagnostic consistency between cognitive and advanced AD biomarkers (β-amyloid and tau) in an effort to improve diagnostic accuracy. Additional areas of interest have included examining the assessment of cognitive change over time, teleneuropsychology, and the detection of early memory decline in elderly and dementia populations through computerized batteries and novel learning measures. He currently serves as Associate Editor of Developmental Neuropsychology and Grand Rounds Editor of The Clinical Neuropsychologist, and has been the Guest Editor for a special issue from the Journal of Clinical and Experimental Neuropsychology. In addition to being the lead neuropsychologist for the multi-center NIA-funded Anti-NMDA Receptor Encephalitis ExTINGUISH trial, he is the past Chair of the Committee on Rural Health of the American Psychological Association (APA), and is currently a Liaison for the Public Interest Advisory Committee, APA Society for Clinical Neuropsychology.

Read more

This Speaker's Sessions

Tuesday Oct. 17
2:30–3:15 PM ET
Watch Replay
Now Live!

New Technologies for Early Detection and Diagnosis of Alzheimer’s

Scaling up technologies for early detection of Alzheimer’s pathology and cognitive impairment promises to transform the global response to Alzheimer’s disease. Digital biomarkers and fluid biomarkers (ranging from cerebrospinal fluid to blood) to detect the disease are advancing rapidly in clinical practice and will enable a more simple, timely, and accurate Alzheimer’s diagnosis.  Key Question: What do these tools and technologies mean for patients and their doctors?

View SessionWatch Replay